ISIS 2922 fomivirsen antisense compound data

Data showing prolonged control of CMV retinitis with the antisense compound ISIS 2922 (fomivirsen) were presented at the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis of CMV Infection in Ft. Myers, Fla. The ongoing, open-label, uncontrolled trial with 107 patients includes patients with refractory disease. Patients are receiving 300 µg per intravitreal injection every other week.

Data also were presented on 25 patients from the unrandomized dose escalation portion of ongoing Phase III trials. The group includes both early and advanced disease patients who received 150 µg of drug either as a single agent therapy or in combination with ganciclovir, also dosed every other week following induction. ...